Millennium Management’s Immunovant IMVT Stock Holding History

Millennium Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-50,000	Closed	-$800K	–	6224
2025 Q2	$800K	Sell	50,000 -5,000	-9%	-$75.6K	﹤0.01%	4583
2025 Q1	$940K	Buy	55,000 +35,000	+175%	+$732K	﹤0.01%	4391
2024 Q4	$495K	Buy	+20,000	New	+$567K	﹤0.01%	4760
2024 Q2	–	Sell	-109,200	Closed	-$3.53M	–	6199
2024 Q1	$3.53M	Buy	109,200 +400	+0.4%	+$14.6K	﹤0.01%	3227
2023 Q4	$4.58M	Buy	+108,800	New	+$4M	﹤0.01%	2868
2022 Q4	–	Sell	-100,000	Closed	-$558K	–	6774
2022 Q3	$558K	Buy	+100,000	New	+$489K	﹤0.01%	4871
2021 Q4	–	Sell	-252,200	Closed	-$2.19M	–	7076
2021 Q3	$2.19M	Sell	252,200 -54,100	-18%	-$488K	﹤0.01%	3801
2021 Q2	$3.24M	Buy	+306,300	New	+$4.28M	﹤0.01%	3339

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Millennium Management's IMVT Position: Q1 2026 in Review

Millennium Management sold out of Immunovant (IMVT) in Q1 2026, closing a stake of 172,496 shares — an estimated $4.38M sold.

Millennium Management first reported a position in IMVT in Q1 2020 and held it in 24 quarters. The position peaked at $28.3M in Q4 2023. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

Millennium Management reported no remaining Immunovant position as of Q1 2026 after selling out during the quarter.
Millennium Management sold 172,496 Immunovant shares in Q1 2026, an estimated $4.38M.
Millennium Management first reported a position in Immunovant in Q1 2020 and held it in 24 quarters.
Millennium Management's Immunovant position peaked at $28.3M in Q4 2023.
215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.